scholarly journals Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in Taiwan

2018 ◽  
Vol 9 (10) ◽  
pp. 1813-1820 ◽  
Author(s):  
Shu-Yung Lin ◽  
Ching-Yao Yang ◽  
Bin-Chi Liao ◽  
Chao-Chi Ho ◽  
Wei-Yu Liao ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Clinical Outcomes ◽  
Real World ◽  
Small Cell ◽  
Advanced Stage ◽  
Small Cell Lung ◽  
Real World Data ◽  
Lung Cancer Patients

scholarly journals PCN5 REAL-WORLD DATA OF NIVOLUMAB IN NON-SMALL-CELL LUNG CANCER PATIENTS IN GREECE

2019 ◽  
Vol 22 ◽  
pp. S435-S436
Author(s):  
G. Kourlaba ◽  
E. Kokkotou ◽  
A. Papaspiliou ◽  
G. Stefanou ◽  
L. Stournara ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Real World ◽  
Small Cell ◽  
Small Cell Lung ◽  
Real World Data ◽  
World Data ◽  
Lung Cancer Patients

scholarly journals Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines

2021 ◽  
Author(s):  
Alessandro Dal Maso ◽  
Martina Lorenzi ◽  
Alessandra Ferro ◽  
Sara Pilotto ◽  
Fabiana Cecere ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Real World ◽  
Small Cell ◽  
Small Cell Lung ◽  
Real World Data ◽  
T790m Mutation ◽  
Lung Cancer Patients

Aims: This study describes real-world outcomes of pretreated EGFR T790M-positive (T790M+) advanced non-small-cell lung cancer patients progressing after first- or second-generation tyrosine kinase inhibitors and receiving osimertinib, compared with T790M-negative (T790M-) patients. We have also described progression patterns and treatment sequences. Patients & methods: This is a retrospective multicenter Italian observational study including consecutive Caucasian patients referred between 2014 and 2018. Results: 167 patients were included. Median progression-free survival was 9.8 months (95% CI: 8.3–13.3) for T790M+ and 6.0 months (95% CI: 4.9–7.2) for T790M- patients, respectively. Median overall survival was 20.7 months (95% CI: 18.9–28.4) for T790M+ and 10.6 months (95% CI: 8.6–23.6) for T790M- patients, respectively. The T790M mutation correlated with absence of new sites of disease. After progression, most T790M+ patients continued osimertinib, whereas most T790M- patients received a different treatment line. Conclusion: Better outcomes were shown in patients receiving osimertinib. A more limited progression pattern for T790M+ was suggested.

scholarly journals Real world data of nivolumab for previously treated non-small cell lung cancer patients: a Galician lung cancer group clinical experience

2018 ◽  
Vol 7 (3) ◽  
pp. 404-415 ◽  
Author(s):  
Mª Carmen Areses Manrique ◽  
Joaquín Mosquera Martínez ◽  
Jorge García González ◽  
Francisco Javier Afonso Afonso ◽  
Martín Lázaro Quintela ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Real World ◽  
Small Cell ◽  
Small Cell Lung ◽  
Real World Data ◽  
Lung Cancer Patients ◽  
Cancer Group ◽  
Previously Treated
Sign in / Sign up

Export Citation Format

Share Document